A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma-Reference-Cited by-同舟云学术

A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma

Published:2022-10-03 Issue:23 Volume:28 Page:5010-5012
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Palanki Rohan¹²^ORCID,Swingle Kelsey L.¹^ORCID,Mitchell Michael J.¹³⁴⁵⁶^ORCID

Affiliation:

1. 1Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania.

2. 2Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

3. 3Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

4. 4Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

5. 5Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

6. 6Institute for Regenerative Medicine, Perelman School of Medicine, Philadelphia, Pennsylvania.

Abstract

SummaryA microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunotherapy.See related article by Nash et al., p. 5121

Funder

Burroughs Wellcome Fund

National Heart, Lung, and Blood Institute

National Institutes of Health

National Science Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-2626/3211708/ccr-22-2626.pdf

Reference13 articles.

1. Activation of adaptive and innate immune cells via localized interleukin-2 cytokine factories eradicates mesothelioma tumors;Nash;Clin Cancer Res,2022

2. Cytokines in clinical cancer immunotherapy;Berraondo;Br J Cancer,2019

3. Systemic immunity in cancer;Hiam-Galvez;Nat Rev Cancer,2021

4. Targeting the tumor stroma to improve cancer therapy;Valkenburg;Nat Rev Clin Oncol,2018